MedTrace Logo

Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization

NCT00074724 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2021-04-08

Study results available
· View outcomes & findings →

Summary

To define the role of the assessment of myocardial viability with dobutamine echocardiography (DE) in the clinical evaluation and selection of the best treatment for a high-risk subset of patients with coronary artery disease.

Conditions

Interventions

PROCEDURE

Coronary Artery Bypass

coronary revascularization using arterial or vein conduits

DRUG

Modern medical management

Therapies with evidence-based recommendations.

DEVICE

Dobutamine echocardiography

Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.

DRUG

Optimal medical therapy

All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Medstar Health Research Institute

    lead OTHER

Principal Investigators

  • Julio Panza · Medstar Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2008-12-31
Completion
2017-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00074724 on ClinicalTrials.gov